Eupraxia Pharmaceuticals Inc. (EPRX): Shareholders' Equity
$82.04M
As of 2025-12-31
+119.2%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $82.04M | +145.6% | 2026-03-13, Balance as of period end |
| 2024-12-31 | $33.40M | n/m | 2026-03-13, Balance as of period end |
| 2023-12-31 | $2.22M | -71.5% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $7.79M | n/a | 2024-04-01, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | 2025-12-31 | $82.04M | +145.6% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare EPRX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗